The pandemic has impacted every practice differently, but the changes it’s wrought may last a long time.
Three unique, non-diffractive/non-multifocal IOLs that strive for a greater range of vision.
Postop results and safety profiles are similar, but there are key differences between the procedures.
The truth may surprise you. Find out the ups and downs and future outlook.
Review of Ophthalmology Online eNewsletter
- Juxtapapillary Dropout & RNFL Thinning in Glaucoma
Find out what eyes with juxtapapillary microvasculature dropout revealed about glaucoma progression.
- Early Experience with Brolucizumab Treatment of nAMD
See how brolucizumab intravitreous injection affected visual acuity, central subfield thickness and intraocular inflammation.
- Infectious Keratitis After Boston Type 1 Keratoprosthesis Implantation
Learn what percentage of people developed infectious keratitis after KPro implantation, and which type of infectious keratitis was more common.
- Imaging Biomarkers to Predict Responsive & Unresponsive Cases Treated with Standardized Anti-VEGF Regimen in nAMD
What factors were useful to predict a poor treatment response?
- Industry News
Continuing Medical Education
Sponsored by RVL Pharmaceuticals
Thought leaders discuss the causes, impact and diagnosis of acquired blepharoptosis.
Andrea Kossler, MD, FACS, Assistant Professor of Ophthalmology, Stanford University Medical Center Director of the Ophthalmic Plastic, Reconstructive Surgery and Orbital Oncology Service, Byers Eye Institute Palo Alto, CaliforniaDavid Wirta, MD, Medical Director and Principal Investigator, Eye Research Foundation Newport Beach, California